ERIS Lifesciences Ltd, engaged in the manufacturing and marketing of pharmaceutical products, reported robust financial results for Q2FY26.
Financial Highlights:
- Revenues increased 6.88% year-on-year to ₹792 crore from ₹741 crore.
- Total expenses rose 1.14% to ₹623 crore from ₹616 crore.
- Consolidated net profit surged 39.58% to ₹134 crore from ₹96 crore.
- Earnings per share improved 31.05% to ₹8.82 from ₹6.73.
The significant profit growth was supported by effective cost management and higher operational efficiencies despite modest revenue growth.
Outlook:
ERIS Lifesciences aims to expand its product portfolio, strengthen sales networks, and enhance R&D capabilities to sustain growth. Continued focus on specialty segments and strategic market expansion are expected to drive future performance.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,